1520-7560/asset/bannerforeground.jpg?v=1&s=97ddd213ca98f827538987e02b801875335d1a52)
Review Article
You have free access to this content
CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health
Article first published online: 7 AUG 2007
DOI: 10.1002/dmrr.764
Copyright © 2007 John Wiley & Sons, Ltd.
1520-7560/asset/cover.gif?v=1&s=518ef24df4af0f53197d5b36e1afedd4421360a2 "Diabetes/Metabolism Research and Reviews")
Additional Information
How to Cite
Cota, D. (2007), CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev., 23: 507–517. doi: 10.1002/dmrr.764
Publication History
- Issue published online: 21 SEP 2007
- Article first published online: 7 AUG 2007
- Manuscript Accepted: 20 JUN 2007
- Manuscript Revised: 16 JUN 2007
- Manuscript Received: 19 JUN 2006
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1
- 2, , , , , Identification of cannabinoid type 1 receptor in dog hair follicles, Acta Histochemica, 2012, 114, 1, 68
- 3, , , , , , Binding properties of antagonists to Cannabinoid receptors in intact cells, Fundamental & Clinical Pharmacology, 2011, 25, 2Direct Link:
- 4, , , , , , Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans, Diabetes, Obesity and Metabolism, 2011, 13, 10Direct Link:
- 5, , , , , , , , , , Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers, Molecular Psychiatry, 2011,
- 6, , , Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas, Pharmacology & Therapeutics, 2011, 129, 3, 307
- 7, , , , , , , Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity, International Journal of Obesity, 2011,
- 8, , , The Metabolic Syndrome—from Insulin Resistance to Obesity and Diabetes, Medical Clinics of North America, 2011, 95, 5, 855
- 9, , , , , , , , , The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat, Pharmacology Biochemistry and Behavior, 2011, 97, 3, 537
- 10, , , , , , Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice, Behavioural Brain Research, 2011, 217, 2, 432
- 11
- 12, , , , , , , , , , Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant, Journal of Neurochemistry, 2010, 112, 5Direct Link:
- 13, , , , Hydrolysis of 2-arachidonoylglycerol in Tetrahymena thermophila. Identification and partial characterization of a Monoacylglycerol Lipase-like enzyme, European Journal of Protistology, 2010, 46, 4, 289
- 14, , , Physical and functional interaction between CB1 cannabinoid receptors and β2-adrenoceptors, British Journal of Pharmacology, 2010, 160, 3Direct Link:
- 15, , , , , The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat, Neurogastroenterology & Motility, 2010, 22, 6Direct Link:
- 16, , , , , A critical review of the cannabinoid receptor as a drug target for obesity management, Obesity Reviews, 2009, 10, 1Direct Link:
- 17, Adipose tissue–skeletal muscle crosstalk: are endocannabinoids an unwanted caller?, Diabetologia, 2009, 52, 4, 571
- 18, , Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions, International Journal of Obesity, 2009, 33, 9, 947
- 19, , , , , FAAH deficiency promotes energy storage and enhances the motivation for food, International Journal of Obesity, 2009, 34, 3, 557
- 20, , , , , , , , Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism, Obesity, 2009, 17, 8, 1641
- 21, , , , , , , , , , , , , , Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 17, 5195
- You have free access to this content22, Cannabinoid Receptors: Where They are and What They do, Journal of Neuroendocrinology, 2008, 20,Direct Link:
- You have free access to this content23, CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant, Journal of Neuroendocrinology, 2008, 20,Direct Link:
- 24Current literature in diabetes, Diabetes/Metabolism Research and Reviews, 2008, 24, 5Direct Link:
- 25, , Physiological, Pharmacological, and Nutritional Regulation of Circulating Adiponectin Concentrations in Humans, Metabolic Syndrome and Related Disorders, 2008, 6, 2, 87
- 26, Taranabant Cuts the Fat: New Hope for Cannabinoid-Based Obesity Therapies?, Cell Metabolism, 2008, 7, 1, 1
- 27, Targeting the endocannabinoid system: to enhance or reduce?, Nature Reviews Drug Discovery, 2008, 7, 5, 438
- You have free access to this content28, , , , The Endocannabinoid System and the Control of Glucose Homeostasis, Journal of Neuroendocrinology, 2008, 20,Direct Link:
- 29, , , , The Endocannabinoid System as a Target for Obesity Treatment, Clinical Cornerstone, 2008, 9, 1, 52
- 30, , , The Metabolic Syndrome—from Insulin Resistance to Obesity and Diabetes, Endocrinology & Metabolism Clinics of North America, 2008, 37, 3, 559